A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Completed
Incyte Corporation
Phase 2
2008-10-01
The study will be a double-blind, randomized, vehicle-controlled study with application of
ruxolitinib phosphate cream or vehicle in patients with stable plaque psoriasis. Application
will be QD for 12 weeks without occlusive dressings. There will be 4 treatments of 50
subjects each.
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Completed
Incyte Corporation
Phase 2
2007-05-01
The study is comprised of two parts. The first portion of this study will be a double-blind,
Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to
paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part
2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA
approved products in patients with active but stable plaque psoriasis.
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Completed
National Cancer Institute (NCI)
Phase 1
2010-09-01
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.
PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424
in treating young patients with relapsed or refractory solid tumor, leukemia, or
myeloproliferative disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
